704 | ORELABRUTINIB PLUS RITUXIMAB AND HIGH‐DOSE METHOTREXATE IN PRIMARY CENTRAL NERVOUS SYSTEM DIFFUSED LARGE B‐CELL LYMPHOMA: A SINGLE‐ARM PHASE II STUDY

Documenti analoghi

• 701 | EFFICACY OF HIGH‐DOSE THIOTEPA, RITUXIMAB, AND POMALIDOMIDE AS A SALVAGE REGIMEN FOR RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
  di: Z. Liu, et al.
  Pubblicazione: (2025)
• 688 | INTRAVENOUS MIDDLE‐DOSE METHOTREXATE INCORPORATED INTO R‐CHOP PREVENTED CENTRAL NERVOUS SYSTEM RELAPSE IN HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS
  di: M. Lang, et al.
  Pubblicazione: (2025)
• 334 | A PHASE I/II STUDY OF ORELABRUTINIB COMBINED WITH ANTI‐PD‐1 ANTIBODY AND FOTEMUSTINE FOR PATIENTS WITH NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
  di: W. Zhao, et al.
  Pubblicazione: (2025)
• 472 | THE HETEROGENEITY AND RELATED PROGNOSTIC FACTORS OF PRIMARY CENTRAL NERVOUS SYSTEM DIFFUSE LARGE B‐CELL LYMPHOMA BASED ON SINGLE‐CELL SEQUENCING TECHNOLOGY
  di: J. Youchao, et al.
  Pubblicazione: (2025)
• 346 | RITUXIMAB‐DOSE‐ADJUSTED EPOCH VERSUS RITUXIMAB‐CHOP IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA
  di: T. Vassilakopoulos, et al.
  Pubblicazione: (2025)